Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06383078
Other study ID # MA-PC-II-012
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date April 20, 2024
Est. completion date December 30, 2027

Study information

Verified date April 2024
Source The First Affiliated Hospital with Nanjing Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of HR070803 in Combination With Oxaliplatin plus Tegafur compared to HR070803 in combination with oxaliplatin, 5-fluorouracil/leucovorin (5FU/LV) treatment as adjuvant therapy in patients with resected pancreatic cancer.


Description:

STUDY DESIGN/ Evaluation criteria Main criterion: efficacy. The main criterion is the 1-year disease-free survival rate. Disease-free survival is defined as the time from date of randomization until the date of the first cancer-related event, second cancer, or death from any cause. Patients without event at the time of analysis will be censored at the date of last follow-up visit. Secondary criteria include Overall survival. OS is defined as the time from date of randomization until the date of death from any cause. Patients who are still living at the time of analysis will be censored at the date of last follow-up visit. Secondary criteria also include the Disease-free survival. Tolerance Patients evaluable for toxicity must have received one investigational drug.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 120
Est. completion date December 30, 2027
Est. primary completion date March 1, 2027
Accepts healthy volunteers No
Gender All
Age group 20 Years to 75 Years
Eligibility Inclusion Criteria: 1. Histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1). 2. ECOG performance status 0 or 1. 3. Life expectancy of greater than or equal to 6 months. 4. Full recovery from surgery and patient is scheduled to start treatment within 3 weeks to 12 weeks after surgery. 5. The number of lymph nodes dissected during resection = 15. 6. Able and willing to provide a written informed consent. Exclusion Criteria: 1. Patients with pancreatic cancer originating from extrapancreatic ductal epithelium, including pancreatic neuroendocrine carcinoma, acinar cell carcinoma of the pancreas, pancreatoblastoma, and solid-pseudopapillary tumor; 2. Presence of or history of metastatic or locally recurrent pancreatic adenocarcinoma. 3. CA19-9 exceeding normal value within 14 days prior to enrollment. 4. Prior neo-adjuvant treatment, radiation therapy, or systemic therapy for pancreatic adenocarcinoma. 5. Severe infection (> CTCAE grade 2), such as severe pneumonia, bacteremia, infection complications, etc. requiring inpatient treatment, occurred within four weeks before enrollment, and symptoms and signs of infection requiring intravenous antibiotic therapy (except for prophylactic antibiotics) occurred within two weeks before enrollment; 6. Patients with cardiac clinical symptoms or diseases that are not well controlled, such as: (1) Patients with NYHA class 2 and above cardiac failure; (2) unstable angina; (3) myocardial infarction that occurred within 6 months; (4) clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
HR070803
HR070803 60 mg/^2 D1 over 90 minutes.
Oxaliplatin
Oxaliplatin 85 mg/^2 D1 over 2 hours.
Tegafur
initial dose of S-1 is determined according to the body surface area,orally, D1-7.
Folinic acid
Folinic acid 400 mg/^2 D1
5-Fluorouracil
5-FU 2400 mg/^2 D1 IV continuous infusion over 46 hours

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
The First Affiliated Hospital with Nanjing Medical University

Outcome

Type Measure Description Time frame Safety issue
Primary 1-year Disease-free survival rate Disease-free survival is defined as the time from date of randomization until the date of the first cancer-related event, second cancer, or death from any cause. Up to 2 years
Secondary Overall survival (OS) OS is defined as the time from date of randomization until the date of death from any cause. Up to 2 years
Secondary Disease-free survival(DFS) Disease-free survival is defined as the time from date of randomization until the date of the first cancer-related event, second cancer, or death from any cause. Up to 2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04759534 - Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia Phase 3
Not yet recruiting NCT05532111 - Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial N/A
Active, not recruiting NCT04284215 - Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLC N/A
Completed NCT06202456 - A Phase IV Study of Huazhi Rougan Granule in the Treatment of Non-alcoholic Simple Fatty Liver Phase 4
Completed NCT04870606 - Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness Phase 3
Completed NCT03660761 - Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors Phase 2
Active, not recruiting NCT03794778 - Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer Phase 4
Recruiting NCT03255343 - Treatment of Non-responding to Conventional Therapy Inoperable Liver Cancers by in Situ Introduction of ImDendrim N/A
Recruiting NCT04197544 - Evaluation of the Implantation of the End-vascular Creation of the Arteriovenous Fistulas in Patients in the University Hospital of Araba. Pilot Study. N/A
Recruiting NCT04518501 - Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer Phase 1/Phase 2
Completed NCT03779776 - The Efficacy and Safety of Early Vitamin AD Supplementation in Very Preterm Infants N/A
Not yet recruiting NCT06218004 - Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma Phase 2
Enrolling by invitation NCT02809079 - Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Phase 4
Active, not recruiting NCT06194188 - A Phase 2 Clinical Study of CU-20401 Phase 2
Recruiting NCT03901235 - MSC Intratissular Injection in Crohn Disease Patients Phase 1/Phase 2
Completed NCT03826004 - Clemastine in Cardiovascular Surgery N/A
Active, not recruiting NCT03623776 - Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC. Phase 2
Recruiting NCT04078399 - Efficacy and Safety of Azacitidine Combined With Interferon in the Treatment of Post-transplant Recurrence N/A
Not yet recruiting NCT06351735 - Efficacy and Safety of Deep Cervical Lymph Node-vein Bypass Surgery in ALS Amyotrophic Lateral Sclerosis
Withdrawn NCT05481775 - Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer Phase 2